Takeaway

• Patients with advanced high-grade serous or endometrioid ovarian cancer have a poor prognosis.
• Bevacizumab use and a deleterious BRCA status were associated with improvement in survival in this real-world population.

Why this matters

• The overall outcomes after surgery and the disease status at the most recent assessment highlight the...